Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C26H39N3O4 |
Molar mass | 457.615 g·mol−1 |
3D model (JSmol) | |
| |
|
Axelopran (INN, USAN) (developmental code name TD-1211) is a drug which is under development by Theravance Biopharma for the treatment of opioid-induced constipation. It acts as a peripherally acting μ-opioid receptor antagonist and also acts on κ-, and δ-opioid receptors, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Axelopran has potent μ-opioid receptor antagonist activity on the gastrointestinal tract in vivo, and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following subcutaneous or oral administration.[1][2]
Stool softeners | |
---|---|
Stimulant laxatives | |
Bulk-forming laxatives | |
Lubricant laxatives | |
Osmotic laxatives | |
Enemas | |
Opioid antagonists | |
Others |